Objective To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVpreF) to protect infants against severe RSV-associated illness. Methods MATISSE was a global, phase 3, […]

Latest updates

From the Ethiopia team

11 OCT

Ethiopia’s Hidden Pneumonia Killer: Why RSV Deserves a Place in the Vaccine Schedule

For decades, Ethiopia has fought pneumonia with the tools it had.  These tools include using vaccines against pneumococcus, Haemophilus influenzae type B and measles, each rolled into the infant immunisation schedule at six, ten and fourteen weeks. Yet the disease remains the leading cause of illness and death among children under five in the country, […]

Language access

View MIRNA content in your preferred language.

Use the language selector in the website header to translate MIRNA content across the site.

English · Kiswahili · Amharic · Bangla · Urdu · French

Partners

Ethiopia network partners

Partner directory

Ethiopia

Explore resources from Ethiopia

Ethiopia projects

Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

From the Ethiopia team

View MIRNA content in your preferred language.

Ethiopia network partners

MIRNA updates, evidence and opportunities